Journal of Preventive Medicine and Public Health

The Korean Society for Preventive Medicine (대한예방의학회)
권호 표지
DOI QR코드

DOI QR Code

Demographic and Survivorship Disparities in Non-muscle-invasive Bladder Cancer in the United States

  • Seo, Munseok (School of Biomedical Informatics, University of Texas Health Science Center) ;
  • Langabeer, James R. II (School of Public Health, University of Texas Health Science Center)
  • Received : 2018.04.18
  • Accepted : 2018.08.10
  • Published : 2018.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: To examine survivorship disparities in demographic factors and risk status for non-muscle-invasive bladder cancer (NMIBC), which accounts for more than 75% of all urinary bladder cancers, but is highly curable with early identification and treatment. Methods: We used the US National Cancer Institute's Surveillance, Epidemiology, and End Results registries over a 19-year period (1988-2006) to examine survivorship disparities in age, sex, race/ethnicity, and marital status of patients and risk status classified by histologic grade, stage, size of tumor, and number of multiple primary tumors among NMIBC patients (n=29 326). We applied Kaplan-Meier (K-M) and Cox proportional hazard methods for survival analysis. Results: Among all urinary bladder cancer patients, the majority of NMIBCs were in male (74.1%), non-Latino white (86.7%), married (67.8%), and low-risk (37.6%) to intermediate-risk (44.8%) patients. The mean age was 68 years. Survivorship (in median life years) was highest for non-Latino white (5.4 years), married (5.4 years), and low-risk (5.7 years) patients (K-M analysis, p<0.001). We found significantly lower survivorship for elderly, male (female hazard ratio [HR], 0.96), Latino (HR, 1.20), and unmarried (married HR, 0.93) patients. Conclusions: Survivorship disparities were ubiquitous across age, sex, race/ethnicity, and marital status groups. Non-white, unmarried, and elderly patients had significantly shorter survivorship. The implications of these findings include the need for a heightened focus on health policy and more organized efforts to improve access to care in order to increase the chances of survival for all patients.

Keywords

References

  1. Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 2012;4(1): 13-32. https://doi.org/10.1177/1756287211431976
  2. National Cancer Institute. Cancer stat facts: bladder cancer [cited 2017 Nov 20]. Available from: https://seer.cancer.gov/statfacts/html/urinb.html.
  3. American Cancer Society. Survival rates for bladder cancer [cited 2018 Jan 3]. Available from: https://www.cancer.org/cancer/bladder-cancer/detection-diagnosis-staging/survival-rates.html.
  4. Cheng L, MacLennan GT, Lopez-Beltran A. Histologic grading of urothelial carcinoma: a reappraisal. Hum Pathol 2012;43(12): 2097-2108. https://doi.org/10.1016/j.humpath.2012.01.008
  5. MacLennan GT, Kirkali Z, Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol 2007;51(4): 889-897. https://doi.org/10.1016/j.eururo.2006.10.037
  6. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(6 Suppl 1):4-34. https://doi.org/10.1016/j.urology.2005.07.062
  7. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64(4):639-653. https://doi.org/10.1016/j.eururo.2013.06.003
  8. Bobinski J, Lipinski M. EORTC risk tables--a new diagnostic tool in urology. Pol Merkur Lekarski 2009;27(162):524-528 (Polish).
  9. Barton MK. High morbidity and mortality found for high-risk, non-muscle-invasive bladder cancer. CA Cancer J Clin 2013; 63(6):371-372. https://doi.org/10.3322/caac.21201
  10. Snyder C, Harlan L, Knopf K, Potosky A, Kaplan R. Patterns of care for the treatment of bladder cancer. J Urol 2003;169(5):1697-1701. https://doi.org/10.1097/01.ju.0000056727.30546.b7
  11. Hollenbeck BK, Dunn RL, Ye Z, Hollingsworth JM, Lee CT, Birkmeyer JD. Racial differences in treatment and outcomes among patients with early stage bladder cancer. Cancer 2010;116(1): 50-56. https://doi.org/10.1002/cncr.24701
  12. Underwood W 3rd, Dunn RL, Williams C, Lee CT. Gender and geographic influence on the racial disparity in bladder cancer mortality in the US. J Am Coll Surg 2006;202(2):284-290. https://doi.org/10.1016/j.jamcollsurg.2005.09.009
  13. Seo KW, Kim BH, Park CH, Kim CI, Chang HS. The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus calmette-guerin instillation. Korean J Urol 2010;51(3):165-170. https://doi.org/10.4111/kju.2010.51.3.165
  14. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163(1):73-78. https://doi.org/10.1016/S0022-5347(05)67975-X
  15. National Cancer Institute. Number of persons by race and Hispanic ethnicity for SEER participants (2010 census data 1) [cited 2018 May 17]. Available from: https://seer.cancer.gov/registries/data.html.
  16. National Cancer Institute. SEER program coding and staging manual 2016; 2016 [cited 2018 May 17]. Available from: https:// seer.cancer.gov/archive/manuals/2016/SPCSM_2016_maindoc.pdf.
  17. National Cancer Institute. Site recode ICD-O-3 (1/27/2003) definition [cited 2018 May 17]. Available from: https://seer.cancer.gov/siterecode/icdo3_d01272003/.
  18. National Cancer Institute. AJCC cancer staging [cited 2018 May 17]. Available from: https://seer.cancer.gov/seerstat/variables/seer/ajcc-stage/.

Cited by

  1. Back pain following instillations of BCG for superficial bladder cancer is not a reactive complication: review of 30 Mycobacterium bovis BCG vertebral osteomyelitis cases vol.38, pp.6, 2018, https://doi.org/10.1007/s10067-019-04500-w
  2. Does Health Insurance Modify the Association Between Race and Cancer-Specific Survival in Patients with Urinary Bladder Malignancy in the U.S.? vol.16, pp.18, 2019, https://doi.org/10.3390/ijerph16183393
  3. Marital Status and Prognostic Nomogram for Bladder Cancer With Distant Metastasis: A SEER-Based Study vol.10, pp.None, 2020, https://doi.org/10.3389/fonc.2020.586458
  4. Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions vol.12, pp.3, 2018, https://doi.org/10.14336/ad.2020.1109
  5. Effect of Intravesical Chemotherapy on the Survival of Patients with Non-Muscle-Invasive Bladder Cancer Undergoing Transurethral Resection: A Retrospective Cohort Study Among Older Adults vol.14, pp.1, 2018, https://doi.org/10.2174/1874303x02114010020
  6. Comparison of survival in elderly patients treated with uretero-cutaneostomy or ileal conduit after radical cystectomy vol.21, pp.1, 2018, https://doi.org/10.1186/s12877-020-01861-9